These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35076567)

  • 1. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.
    Nepal G; Khurana M; Bucheli DH; Bhandari S; Joshi U; Bhagat R; Rehrig JH; Pudasainee P; Shing YK; Ortiz JF; Ojha R; Gajurel BP; Quinonez J; Ruxmohan S; Albert T; Licata S; Stien J
    Neurol Int; 2022 Jan; 14(1):99-108. PubMed ID: 35076567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review.
    Guo HP; Dang XL; Kang L; Liu C; Liu XW
    World Neurosurg; 2024 Aug; 188():161-169. PubMed ID: 38641241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
    Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
    Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
    Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
    Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
    Sasaki N; Nagane M
    No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
    Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
    Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma.
    Yang Y; Li Q; Ma J; Kang H; Lin Z; Wang Y; Ma Y; Chen B
    Front Oncol; 2023; 13():1098785. PubMed ID: 37182159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphomas of Central Nervous System.
    Yokogami K; Azuma M; Takeshima H; Hirai T
    Adv Exp Med Biol; 2023; 1405():527-543. PubMed ID: 37452952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.
    Mendez JS; Grommes C
    Am Soc Clin Oncol Educ Book; 2018 May; 38():604-615. PubMed ID: 30231317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report.
    Zhou Y; Wang X; Lin X; Wang J; Yan X; Wen Y
    AIDS Res Ther; 2023 Aug; 20(1):63. PubMed ID: 37644480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary central nervous system lymphoma.
    Schaff LR; Grommes C
    Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II study assessing Long-Term Response to Ibrutinib Monotherapy in recurrent or refractory CNS Lymphoma.
    Grommes C; Nandakumar S; Schaff LR; Gavrilovic I; Kaley TJ; Nolan CP; Stone J; Thomas AA; Tang SS; Wolfe J; Bozza A; Wongchai V; Hyde A; Barrett E; Lynch EA; Madzsar JT; Lin A; Piotrowski AF; Pentsova E; Francis JH; Hatzoglou V; Schultz N; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Clin Cancer Res; 2024 Jul; ():. PubMed ID: 38995739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis.
    Lv L; Sun X; Wu Y; Cui Q; Chen Y; Liu Y
    Front Oncol; 2021; 11():707285. PubMed ID: 34277452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targets and treatments in primary CNS lymphoma.
    von Roemeling C; Ferreri AJM; Soussain C; Tun HW; Grommes C
    Leuk Lymphoma; 2024 Aug; 65(8):1055-1067. PubMed ID: 38659230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of primary central nervous system lymphoma.
    Han CH; Batchelor TT
    Cancer; 2017 Nov; 123(22):4314-4324. PubMed ID: 28950405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review].
    Hu BN; Yang X; Yuan YP; Chen YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):633-637. PubMed ID: 33812443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
    T Low J; B Peters K
    CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and Outcomes of Primary Central Nervous System Lymphoma: A Retrospective Study of 91 Cases in a Chinese Population.
    Mao C; Chen F; Li Y; Jiang X; Liu S; Guo H; Huang L; Wei X; Liang Z; Li W; Tang K
    World Neurosurg; 2019 Mar; 123():e15-e24. PubMed ID: 30326304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary central nervous system lymphoma.
    Löw S; Han CH; Batchelor TT
    Ther Adv Neurol Disord; 2018; 11():1756286418793562. PubMed ID: 30305848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances and challenges in primary central nervous system lymphoma: a narrative review.
    Ma L; Gong Q
    Transl Cancer Res; 2023 May; 12(5):1335-1352. PubMed ID: 37304530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.